Related Experiment Video
Updated: Apr 21, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
Molecular evaluation of HBV core gene mutations in asymptomatic HBV infected blood donors in Iran
Soad Ghabeshi1, Ruhollah Baktashi2, Seyed Masoud Hosseini3
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran Departments of Microbiology, Faculty of Biological Science, Shahid Beheshti University, G.C, Tehran, Iran. z.sharifi@ibto.ir.
Insights
Mutations in the Hepatitis B virus (HBV) core gene are common in Iranian blood donors, leading to reduced HBeAg and immune escape. This impacts chronic hepatitis and liver cancer risk.
Area of Science:
- Virology
- Hepatology
- Molecular Biology
Background:
- Mutations in Hepatitis B virus (HBV) core promoter and precore regions down-regulate HBeAg.
- These mutations are linked to chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC).
Purpose of the Study:
- To perform sequence analysis of the HBV core gene in HBsAg-positive blood donors in Iran.
- To investigate the prevalence and impact of HBV core gene mutations in asymptomatic carriers.
Main Methods:
- Serological markers (HBsAg, HBeAg, HBeAb, HBcAb) were measured by ELISA.
- HBV DNA was extracted, and PCR was performed on the core gene.
- Direct sequencing and line probe assay were used for mutation detection and phylogenetic analysis.
Main Results:
- 87.8% of HBV DNA-positive donors were HBeAg negative.
- Precore (PC) and core promoter (BCP) mutants were found in 12% and 55% of donors, respectively.
- Mutations led to amino acid changes in B cell, T helper, and CTL epitopes, reducing antigenicity.
Conclusions:
- Hepatitis B virus infected blood donors in Iran frequently exhibit core gene mutations.
- These mutations reduce HBe and HBc antigenicity, contributing to immune escape in asymptomatic carriers.
- The findings highlight the role of HBV mutations in the pathogenesis of chronic hepatitis and HCC.
Abstract:
Mutations in the core promoter and precore regions of HBV cause down-regulation of HBeAg. These mutations are associated with chronic hepatitis, cirrhosis and Hepato Cellular Carcinoma (HCC). This study was carried out to sequence analysis of HBV core gene in HBsAg- positive blood donors in Iran. A total of 50 HBsAg- positive blood donor samples were examined in this study. Serological markers of hepatitis B including: HBsAg, HBeAg, HBeAb and HBcAb were measured by ELISA method. HBV-DNA was extracted from the sera, and then PCR was performed on extracted HBV-DNA using specific primer of gene C. After direct sequencing, the nucleotide sequences from 50 blood donors were analyzed using a reference sequences and then phylogenetic analysis was performed. Also, the line probe assay was used to detect mutations. The majority of donors (62.5%) were in the age group of 29 - 40 years old. Among all the HBV DNA positive cases, 87.8% were HBeAg negative. The prevalence of PC and BCP mutants were 12% and 55% respectively, among asymptomatic HBV infected blood donors by direct sequencing method. The results of this study showed that some of HBV infected blood donors had mutation in core gene of HBV and amino acid changes in B cell, T helper and CTL epitopes that can cause reducing HBe and HBc antigenicity in asymptomatic HBV infected blood donors and the development of escape mutants from host immune.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
11:28Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
Published on: March 13, 2015
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...